D-2804 27

WHAT IS CLAIMED IS:

5

- 1. A composition comprising:
 - a liquid medium;
- a cyclodextrin component in an amount in a range of about 0.1% to about 30% (w/v); and
- a chlorite component in an effective preserving amount.
 - 2. The composition of claim 1 wherein the liquid medium is an aqueous liquid medium.
 - 3. The composition of claim 1 wherein the cyclodextrin component is selected from the group consisting of β -cyclodextrin, derivatives of β -cyclodextrin and mixtures thereof.
 - 4. The composition of claim 1 wherein the chlorite component is present in an amount of about 500 ppm (w/v) or less.
 - 5. The composition of claim 1 wherein the chlorite component is present in an amount in a range of about 10 ppm(w/v) to about 200 ppm(w/v).
 - 6. The composition of claim 1 wherein the chlorite component is stabilized chlorine dioxide.
 - 7. The composition of claim 1 which further comprises an active component in an amount effective in providing a desired effect to a human or an animal after the composition is administered to the human or animal.

5

- 8. The composition of claim 7 wherein the active component is a pharmaceutically active component effective in providing a desired therapeutic effect to the human or animal after the composition is administered to the human or animal.
 - 9. A composition comprising:
 - a liquid medium;

a cyclodextrin component in an amount in a range of about 0.1% to about 30% (w/v); and

- a preservative component in an effective preserving amount, the preservative component having a greater preservative efficacy in the composition relative to an identical amount of benzalkonium chloride.
 - 10. The composition of claim 9 wherein preservative component forms a complex with the cyclodextrin component to a lesser degree than benzalkonium chloride.
 - 11. The composition of claim 9 wherein the liquid medium is an aqueous liquid medium, and the preservative component is present in an amount of less than about 0.8% (w/v).
 - 12. The composition of claim 9 wherein the preservative component is present in an amount in a range of about 10 ppm(w/v) to about 200 ppm(w/v).
 - 13. The composition of claim 10 wherein the cyclodextrin component is selected from the group consisting of β -cyclodextrin, derivatives of β -cyclodextrin and mixtures thereof.

5

5

- 14. The composition of claim 9 wherein the preservative component is selected from the group consisting of chlorite components, sorbic acid components and mixtures thereof.
- 15. The composition of claim 9 wherein the preservative component is stabilized chlorine dioxide.
- 16. The composition of claim 9 wherein the preservative component is selected from the group consisting of sorbic acid, sorbates and mixtures thereof.
- 17. The composition of claim 9 which further comprises an active component in an amount effective in providing a desired effect to a human or an animal after the composition is administered to the human or animal.
- 18. The composition of claim 17 wherein the active component is a pharmaceutically active component effective in providing a desired therapeutic effect to the human or animal after the composition is administered to the human or animal.
- 19. The composition of claim 9 which is substantially free of inclusion complexes of the cyclodextrin component and the preservative component.

20. A composition comprising:

a liquid medium;

an active component in an amount effective in providing a desired effect to a human or an animal after the composition is administered to the human or animal;

a cyclodextrin component in an amount effective to increase the apparent solubility of the active

10

5

5

component in the liquid medium or to enhance the stability of the active component in the composition or to reduce unwanted side effects of the active component; and

a preservative component in an effective preserving amount, the preservative component having greater preservative efficacy in the composition relative to an identical amount of benzalkonium chloride.

- 21. The composition of claim 20 wherein the liquid medium is an aqueous liquid medium.
- 22. The composition of claim 20 wherein the active component is a pharmaceutically active component effective in providing a desired therapeutic effect to the human or animal after the composition is administered to the human or animal.
- 23. The composition of claim 21 wherein the active component is a pharmaceutically active component effective in providing a desired therapeutic effect to the human or animal after the composition is administered to the human or animal.
- 24. The composition of claim 20 wherein the cyclodextrin component is selected from the group consisting of β -cyclodextrin, derivatives of β -cyclodextrin and mixtures thereof.
- 25. The composition of claim 20 wherein the cyclodextrin component is present in an amount in a range of about 0.1% to about 30% (w/v).
- 26. The composition of claim 20 wherein the preservative component forms a complex with the

cyclodextrin component to a lesser degree than does benzalkonium chloride.

- 27. The composition of claim 20 wherein the preservative component is present in an amount of about 1% (w/v) or less.
- 28. The composition of claim 20 wherein the preservative component is present in an amount in a range of about 10 ppm (w/v) to about 200 ppm (w/v).
- 29. The composition of claim 20 wherein the preservative component is selected from the group consisting of chlorite components, sorbic acid components and mixtures thereof.
- 30. The composition of claim 29 wherein the preservative component is stabilized chlorine dioxide.